Abstract
Despite recent advances in treatment of #osteoporosis and the
availability of new agents #bisphosphonates are still the cornerstone
of osteoporosis treatment due to their #safety, #efficacy and relatively
reasonable costs. On the other hand, the presence of rare side effects
has brought to the agenda that these drugs should be given during
limited time periods. The current approach is to perform #dynamicrisk
identification in patients and to determine the type and duration of the
treatment accordingly.
For more biomedical open access journals please click on
Duration of Biphoshonate #Therapy in #Osteoporosis: Where Do We Stand Today? by Hande Mefkure Ozkaya in BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.